GlassScriptPhysician profile
Manuel S Naron
NPI 1528066362
$3,300.80
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,559 · 2020: $283 · 2021: $78.67 · 2022: $37.30 · 2023: $179 · 2024: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $335.54 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $329.12 | 2019-2020 | |
| Novo Nordisk INC | $323.86 | 2019-2024 | Wegovy |
| Nevro Corp. | $303.78 | 2021-2024 | Senza |
| Horizon Therapeutics Plc | $207.99 | 2019 | |
| Lilly USA, LLC | $199.57 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $169.86 | 2019 | |
| Amgen INC. | $157.11 | 2019 | |
| Abbvie INC. | $149.16 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $115.92 | 2019 | |
| Akebia Therapeutics INC | $79.73 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.88 | 2019 | |
| Gilead Sciences, INC. | $77.28 | 2019-2020 | |
| Glaxosmithkline, LLC. | $71.76 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $69.92 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $63.23 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.90 | 2019 | |
| Abbott Laboratories | $58.88 | 2022-2024 | Freestyle Libre 3 |
| Antares Pharma, INC. | $56.38 | 2019 | |
| Neuronetics, INC. | $52.73 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $50.60 | 2019 | |
| Zyla Life Sciences, INC. | $41.19 | 2019 | |
| Amarin Pharma, INC. | $31.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.52 | 2019 | |
| Shire North American Group INC | $25.66 | 2019 | |
| Roche Diagnostics Corporation | $22.01 | 2020 | |
| Ironshore Pharmaceuticals INC. | $21.68 | 2019 | |
| Emd Serono, INC. | $20.72 | 2021 | |
| Jazz Pharmaceuticals INC. | $20.22 | 2019 | |
| Acclarent, INC | $16.39 | 2019 | |
| Eisai INC. | $14.26 | 2019 | |
| Endo Pharmaceuticals INC. | $12.68 | 2020 | |
| Daiichi Sankyo INC. | $12.50 | 2019 | |
| Pfizer INC. | $12.30 | 2019 | |
| Hikma Pharmaceuticals USA | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Naron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.